/SDGR
SDGR Stock - Schrödinger, Inc.
Healthcare|Medical - Healthcare Information ServicesNASDAQ
$17.66+2.67%
+$0.46 (+2.67%) • Dec 19
49
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.19
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).65
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.57
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+7.6%upside
Target: $19.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SDGR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$17.48 – $17.84
TARGET (TP)$19.00
STOP LOSS$16.25
RISK/REWARD1:1.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.57
52W High$28.47
52W Low$15.99
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $207.54M | $216.67M | $180.96M | $137.93M | $108.09M |
| Gross Profit | $132.08M | $140.69M | $101.02M | $65.62M | $63.47M |
| Gross Margin | 63.6% | 64.9% | 55.8% | 47.6% | 58.7% |
| Operating Income | $-209,296,000 | $-177,448,000 | $-146,817,000 | $-111,443,000 | $-60,916,000 |
| Net Income | $-187,123,000 | $40.72M | $-149,186,000 | $-100,393,000 | $-24,463,000 |
| Net Margin | -90.2% | 18.8% | -82.4% | -72.8% | -22.6% |
| EPS | $-2.57 | $0.57 | $-2.10 | $-1.43 | $-0.44 |
Company Overview
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
33%
Hold / Neutral
4
67%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
2 Bullish4 Neutral/Bearish
Price Targets
$30
Average Target
↑ 67.4% Upside
Now
$19
Low
$30
Average
$60
High
Based on 9 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 15th 2025 | BofA Securities | Upgrade | Buy | $24 |
| September 30th 2025 | Goldman | Initiation | Neutral | $19 |
| August 15th 2025 | Citigroup | Downgrade | Neutral | $20 |
| August 14th 2025 | Barclays | Initiation | Overweight | $25 |
| July 3rd 2025 | Morgan Stanley | Resumed | Equal Weight | $28 |
| July 2nd 2024 | Leerink Partners | Initiation | Outperform | $29 |
| December 5th 2023 | KeyBanc Capital Markets | Initiation | Overweight | $38 |
| May 5th 2023 | Piper Sandler | Resumed | Overweight | $60 |
| December 19th 2022 | Goldman | Initiation | Neutral | $23 |
Earnings History & Surprises
SDGRBeat Rate
44%
Last 18 quarters
Avg Surprise
-6.5%
EPS vs Estimate
Beats / Misses
8/10
Last 12 quarters
Latest EPS
$-0.45
Q4 2025
EPS Surprise History
Q1 24
-7.9%
$-0.41vs$-0.38
Q2 24
-1.3%
$-0.76vs$-0.75
Q3 24
+12.9%
$-0.74vs$-0.85
Q4 24
+13.3%
$-0.52vs$-0.60
Q1 25
-57.1%
$-0.55vs$-0.35
Q2 25
-15.5%
$-0.82vs$-0.71
Q3 25
+28.9%
$-0.59vs$-0.83
Q4 25
+40.0%
$-0.45vs$-0.75
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $-0.13 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.75 | $-0.45 | +40.0% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $-0.83 | $-0.59 | +28.9% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $-0.71 | $-0.82 | -15.5% | ✗ MISS |
Q1 2025 | Feb 26, 2025 | $-0.35 | $-0.55 | -57.1% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.60 | $-0.52 | +13.3% | ✓ BEAT |
Q3 2024 | Jul 31, 2024 | $-0.85 | $-0.74 | +12.9% | ✓ BEAT |
Q2 2024 | May 1, 2024 | $-0.75 | $-0.76 | -1.3% | ✗ MISS |
Q1 2024 | Feb 28, 2024 | $-0.38 | $-0.41 | -7.9% | ✗ MISS |
Q4 2023 | Nov 1, 2023 | $-0.71 | $-0.86 | -21.1% | ✗ MISS |
Q3 2023 | Aug 2, 2023 | $-0.43 | $-0.21 | +51.2% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $1.36 | $-0.38 | -127.9% | ✗ MISS |
Q1 2023 | Feb 28, 2023 | $-0.53 | $-0.38 | +28.3% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-0.65 | $-0.56 | +13.8% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.61 | $-0.67 | -9.8% | ✗ MISS |
Q2 2022 | May 4, 2022 | $-0.52 | $-0.48 | +7.7% | ✓ BEAT |
Q1 2022 | Feb 24, 2022 | $-0.39 | $-0.43 | -10.3% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.43 | $-0.49 | -14.0% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-0.33 | $-0.49 | -48.5% | ✗ MISS |
Latest News
B of A Securities Upgrades Schrodinger to Buy, Maintains Price Target to $24
📈 PositiveBenzinga•Dec 15, 2025, 11:47 AM
Schrodinger Affirms FY2025 Sales Guidance of $243.440M-$257.460M vs $249.717M Est
➖ NeutralBenzinga•Nov 5, 2025, 09:14 PM
Schrodinger Q3 Adj. EPS $(0.57) Beats $(0.71) Estimate, Sales $54.324M Beat $51.557M Estimate
📈 PositiveBenzinga•Nov 5, 2025, 09:11 PM
Copernic Catalysts Surpasses Final Technical Milestone For Its Jointly-Developed Ammonia Synthesis Catalyst With Schrodinger
📈 PositiveBenzinga•Oct 30, 2025, 11:38 AM
Keybanc Maintains Overweight on Schrodinger, Lowers Price Target to $28
➖ NeutralBenzinga•Oct 8, 2025, 01:16 PM
Goldman Sachs Initiates Coverage On Schrodinger with Neutral Rating, Announces Price Target of $19
➖ NeutralBenzinga•Sep 30, 2025, 12:37 PM
Schrödinger Announces A Separation And Release Of Claims Agreement With Dr. Geoffrey Porges As Executive Vice President And CFO
➖ NeutralBenzinga•Sep 8, 2025, 08:24 PM
Morgan Stanley Maintains Equal-Weight on Schrodinger, Lowers Price Target to $19
➖ NeutralBenzinga•Aug 18, 2025, 01:49 PM
Schrodinger drops 16% as it abandons leukemia candidate
📉 NegativeSeeking Alpha•Aug 14, 2025, 12:55 PM
Schrödinger slides after early-stage trial data for cancer therapy
📉 NegativeSeeking Alpha•Jun 12, 2025, 03:05 PM
Frequently Asked Questions about SDGR
What is SDGR's current stock price?
Schrödinger, Inc. (SDGR) is currently trading at $17.66 per share. The stock has moved +2.67% today.
What is the analyst price target for SDGR?
The average analyst price target for SDGR is $19.00, based on 1 analyst.
What sector is Schrödinger, Inc. in?
Schrödinger, Inc. operates in the Healthcare sector, specifically within the Medical - Healthcare Information Services industry. The company is traded on the NASDAQ exchange.
What is SDGR's market cap?
Schrödinger, Inc. has a market capitalization of $1.30 billion, making it a small-cap company.
Does SDGR pay dividends?
No, Schrödinger, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABCL
AbCellera Biologics Inc.
$3.60
Mkt Cap: $1.1B
AZTA
Azenta, Inc.
$34.43
Mkt Cap: $1.6B
EVO
Evotec SE
$2.95
Mkt Cap: $1.0B
IMNM
Immunome, Inc.
$21.44
Mkt Cap: $2.0B
OMCL
Omnicell, Inc.
$46.84
Mkt Cap: $2.2B
OMDA
Omada Health
$14.50
Mkt Cap: $0.8B
PGNY
Progyny, Inc.
$26.63
Mkt Cap: $2.3B
PHR
Phreesia, Inc.
$16.55
Mkt Cap: $1.0B
TDOC
Teladoc Health, Inc.
$7.23
Mkt Cap: $1.3B
TXG
10x Genomics, Inc.
$16.05
Mkt Cap: $2.0B
Explore stocks similar to SDGR for comparison